LSD Treatment for Persons With Alcohol Use Disorder

Status Not yet recruiting

Clinical Trial Summary

Alcohol use causes more overall harm than any other drug and is the seventh leading risk factor for both deaths and disability-adjusted life years. Alcohol use disorders (AUD) are among the most common and undertreated mental disorders in developed countries. Pharmacological and psychotherapeutic treatments only show limited efficacy and around 60% of the patients relapse in the short-term after withdrawal. Lysergic acid diethylamide (LSD) was investigated in numerous clinical trials during the 1950s and 1960s. Specifically, the use of LSD in the treatment of AUD was investigated extensively. A pooled analysis of six historical clinical trials demonstrated, that a single dose of LSD significantly reduced alcohol use at three and six months after LSD administration. However, these trials are limited by several factors, including the use of diagnostic standards that are no longer not up to date, single, high-dose treatment regimes, missing biological assessment for alcohol use, and no consequent assessment of blinding. Therefore, the present study aims to evaluate the safety and efficacy of LSD for the treatment of AUD and addresses the shortcomings of previous studies. The trial has a double-blind, active placebo-controlled, randomized, parallel design and will be conducted in specialized treatment centers for addictive disorders in Switzerland. The study will include 126 patients after withdrawal treatment and will primarily assess the efficacy of LSD for the treatment of AUD. Patients will be treated using a 1:1 allocation. Each arm will last 20 weeks and will comprise nine study visits without drug administration and two study days involving LSD or active placebo administration. In the first session, patients in the treatment group will receive a dose of 150 µg LSD, followed by another 150 µg or 250 µg LSD in the second session, which will take place approximately 4 weeks after the first session. The primary outcome is the mean of percent heavy drinking days after administration of two doses of LSD at 3 months follow-up. Additionally, the study will assess neurobiological mechanisms of action and several other measures.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05474989
Study type	Interventional
Source	University Hospital, Basel, Switzerland
Contact	Felix Müller, PD Dr. med.
Phone	+41 (0)61 325 5111
Email	felix.mueller@upk.ch
Status	Not yet recruiting
Phase	Phase 2
Start date	June 1, 2024
Completion date	May 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04927364` - Examining the Effectiveness of Deep TMS in Veterans With Alcohol Use Disorder	N/A
Active, not recruiting	`NCT04618653` - Comprehensive Process Model of AA-related Behavior Change
Recruiting	`NCT05471154` - Non-invasive Brain Stimulation of the Prefrontal Cortex in Substance Use Disorders	N/A
Completed	`NCT05021640` - Study of DCR-AUD in Healthy Volunteers	Phase 1
Not yet recruiting	`NCT05064228` - Mobile Rewarding Activity Centered Treatment	N/A
Completed	`NCT04958655` - Mental Imagery Intervention for Alcohol Craving	N/A
Completed	`NCT05252221` - Alcohol Telemedicine Consultation in Primary Care (ATC)	N/A
Completed	`NCT06108115` - Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder	N/A
Not yet recruiting	`NCT06303778` - Combining a Smartphone App With Medications to Manage Heavy Drinking	N/A
Completed	`NCT04639895` - Cognitive Rehabilitation Through Personalized Virtual Reality and Paper-and-pencil Interventions in the Alcohol Use Disorder Treatment.	N/A
Completed	`NCT02911285` - NAC for Treating Comorbid PTSD and SUD	Phase 2
Recruiting	`NCT04598399` - Comparison of the Effectiveness of Two Psycho-physical Interventions: Mindfulness Based Relapse Prevention (MBRP) and Unguided Meditative Relaxation in Patients With Alcohol Use Disorder	N/A
Completed	`NCT04827056` - Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study	Phase 1
Completed	`NCT04974645` - Pilot: Digital Therapeutic vs Education for the Management of Problematic Substance Use	N/A
Recruiting	`NCT05992272` - Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer
Completed	`NCT04229095` - Medication Development in Alcoholism: Suvorexant Versus Placebo	Phase 2
Recruiting	`NCT05534568` - The Oklahoma Parent-Child Assistance Program	N/A
Completed	`NCT04925570` - The Anchor Study: Digitally Delivered Intervention for Reducing Problematic Substance Use	Phase 2
Active, not recruiting	`NCT05492942` - Records for Alcohol Care Enhancement	N/A
Recruiting	`NCT05015881` - Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

LSD Treatment for Persons With Alcohol Use Disorder — LYSTA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms